Alkermes (ALKS) stock

Medicines , market cap $7.5B

Medicines for unmet medical needs

Worth $7.5B

$46.47

+0.65%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Above Average

In its industry

#19of 90

Pharma

Checks firing

8of 14

Trending up

From 52-week high

-16.5%

under its best in a year

ALKS's Quality Score rose 2 points on Tue, Nov 10, to 11. Its price is above its average prices of the last 8, 21, 50, and 200 days, which line up in that order (4 chart checks started).

Follow ALKS's trial news. Pro members can get an alert when Alkermes files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ALKS files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2026“…as we enroll the phase 3 Brilliance Studies and work to complete the Vibrance-3 phase 2 study in IH this year…”Trial start · SEC filing · Jun 15

Why is ALKS up?

Up 41% in a year while the S&P 500 rose 12%.

Its Nov 3 results: Total Proprietary Net Sales were $417.3M, from $317.4M a year before; VIVITROL was $127.6M, from $121.1M. It rose 2% on Nov 3.

Sources: Price history, Nov 9, 2026; Company release, Nov 3, 2026

1 more reason, free with an account →1 more reason why ALKS beats the market, from its filings, with the other side, the timeline, and its peers, for Pro members.

Key facts on ALKS

Key facts on ALKS
The chart	Above every average
Latest filing	8-K, Nov 3 Reported its quarterly results

1 more reason behind ALKS's 11, free with an account →2 more reasons behind ALKS's 11, for Pro members.

ALKS in the news

Tue Nov 3Alkermes plc Reports Third Quarter 2026 Financial Results SEC filing 8:09 AM ET · Business Wire and 1 more ALKS closed +1.8% that day.

What's next

Tue Nov 10: Stifel Healthcare Conference 2026Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

ALKS catalysts

Coming up

After its last 4 reports it closed -0.8% on average, higher 2 of 4 times.

5 more coming up and 39 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for ALKS

Next step the company has named

2026“…forward to continuing our momentum in the alixorexton development program as we enroll the phase 3 Brilliance Studies and work to complete the Vibrance-3 phase 2 study in IH this year.”Trial start · SEC filing · Jun 15

What it means: when a trial begins, or reaches the stage the company named.

A trial underway: Brilliance NT1Phase 3 · Recruiting · 150 people · main data estimated May 2027 · NCT07455383

8 more trials, 1 with data due this year, 46 filings, for Pro members.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

EVP, CLO, Alkermes, Inc. David Joseph Gaffin sold 2,035 shares on Nov 3, under a planned sale. 25 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Blair Jackson buys or sells

For Pro members: every trade, and Blair Jackson’s 13 filings and quotes.

Get an alert when ALKS files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why ALKS scores 11

Above Averagefor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means

+8Chart checks 8 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Persistence adds
News adds

No effect today: Run-up, Size, Growth, Dilution, Volatility, and Cash flow.

What every line is worth, and the reason behind it, on ALKS and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when ALKS's Quality Score turns up

A free account. No card.

How ALKS ranks in Pharma

ALKS is #19 of 90 by Quality Score.

How ALKS ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	10/14	23
2	LLYEli Lilly	8/14	21
3	PFEPfizer	6/14	17
	ACBAurora Cannabis		Open for its score
	ACHVAchieve Life Sciences		Open for its score
	ALMSAlumis		Open for its score
	ANNXAnnexon		Open for its score
19	ALKSAlkermes	8/14	11

Net income over four quarters: ALKS -$351K, TEVA $506M, AMRX $133M, INSM -$606M.

When does ALKS report earnings, and what happens after?

Expected to report Wed Feb 24, before the open (in 106 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ALKS reported on Nov 3, 2026

The quarter

Sales of $480.1M, 22% more than a year ago; a profit of $0.09 a share, from $0.49.

“During the quarter, the company recorded VIVITROL revenue of approximately $8 million related to gross-to-net favorability, primarily driven by favorable patient mix.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Productup 31%	$417M77%	$412M83%	$317M81%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 3)

7 more lines, for Pro members.

The outlook

No outlook figures read from this release.

In the company's words

“During the quarter, the company recorded ARISTADA revenue of approximately $3 million related to gross-to-net favorability, primarily driven by favorable patient mix.”

From its results filing (SEC filing · Nov 3)

1 more sentence, for Pro members.

The numbers

Market value: $7.5B; today
Sales: $1.8B; up 15.3% on the year
Free cash flow: $227M; last 12 months

Sales grew 7.3% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 1.2% a year over 5 years.

5 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ALKS: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+6.1%-4.2%+1.8%

May 5Jul 28Nov 3

Reported	When	Gap	Reaction	5 days
Nov 3, 2026Before open	Before open	+2.9%	+1.8%	+2.9%
Jul 28, 2026Before open	Before open	-4.4%	-4.2%	-6.1%
May 5, 2026Before open	Before open	+3.2%	+6.1%	+3.8%

ALKS closed higher after 2 of its last 4 reports.

All 4 reports, and ALKS's Quality Score going into each

ALKS sales and profit by year

Sales and profit by year

Sales grew in three of the last seven years, to $1.5B in 2025. It made a profit in three of the eight years.

ALKS has 8 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ALKS, and all 14 on every stock.Get in free →

ALKS RSI today: 62.3, above its 50-day and 200-day averages

Not scored

RSI 62.3, MACD above signal, above both averages. Not scored.13 readings

The deep dive on ALKS

What it does and how it makes money7 findingsManufactured Product And Royalty made up 20% of its revenue in fiscal 2025 ($291M of $1.48B), against 30% in fiscal 2024; product sales 80%.SEC filing · Feb 25, 2026"We own one unexpired Orange-Book listed U.S. patent covering VIVITROL, which expires in the U.S. in 2029." (10-K for fiscal 2025)SEC filing · Feb 25, 2026
Where it stands3 findingsFor Pro members3 findings on where ALKS stands: its cash, debt, and share count, for Pro members
What changed in its filings4 findings"On July 30, 2026, Avadel CNS Pharmaceuticals, LLC and Flamel Ireland Limited, two wholly-owned subsidiaries of the Company, filed a patent infringement lawsuit against Granules India Limited ('Granules') in the U.S. District Court for the District of New Jersey (the 'NJ District Court')." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 3, 2026Mc kesson corporation made up 31% of its revenue in fiscal 2025, up from 25% in fiscal 2024; Cencora incorporation made up 20%, up from 15% in fiscal 2024.SEC filing · Feb 25, 2026
Who holds and trades it4 findingsFor Pro members4 findings on who holds and trades ALKS, for Pro members
Against its closest peers3 peersNet income over four quarters: ALKS -$351K, TEVA $506M, AMRX $133M, INSM -$606M.

14 more findings on ALKS, each with its source, for Pro members.

ALKS insider trades

2 insiders sold $2.9M across 2 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellNancy Lynn Snyderman$2.2MDirectorat $50.35 on Aug 3, filed Aug 3

SellNancy Lynn SnydermanDirector$2.2Mat $50.35 on Aug 3, filed Aug 3

ALKS trades by Congress and the executive branch

5 trades disclosed in the last six months. The newest:

BuyGilbert Cisneros$1K to $15KHousetraded Sep 29, disclosed Oct 12(13 days later)

BuyGilbert CisnerosHouse$1K to $15Ktraded Sep 29, disclosed Oct 12(13 days later)

All 5 trades on ALKS disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

ALKS's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Joshua ReedSVP, Chief Financial Officer · no trades on file
Craig C. HopkinsonEVP R&D, Chief Medical Officer · 12 trades
David Joseph GaffinEVP, CLO, Alkermes, Inc. · 10 trades
Christian Todd NicholsSVP, Chief Commercial Officer · 2 trades
Samuel Joseph ParisiVP, Finance (Interim PAO) · 2 trades
Blair Curtis JacksonEVP, Chief Operating Officer · no trades on file
Christopher I. WrightDirector · 1 trade
Nancy Lynn SnydermanDirector · 1 trade

7 more officers and directors file at ALKS.

See insider trades by person

Which ETFs hold ALKS?

In ETFs: ALKS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Alkermes

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

2,050 employeesDublin 4alkermes.com

What Alkermes says it competes with

“We face intense competition in the development, manufacture, marketing and commercialization of our products from many and varied sources, such as research institutions and biopharmaceutical companies, including other companies with similar technologies.”

From its annual report, SEC filing · Feb 25, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ALKS and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move ALKS's score: 6 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 12Gilbert Cisneros bought ALKS$1K to $15K, disclosed Oct 12

Alerts are optional.

See ALKS's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: ALKS's Quality Score is 11 (Above Average), #19 of 90 in Pharma. Insiders sold $2.9M in the last 6 months (Form 4).

What does ALKS's Quality Score say?

ALKS scores 11 today, which Breakaway calls Above Average. It is #19 of 90 in Pharma by Quality Score, with 8 of 14 chart checks firing. Up 41% in a year while the S&P 500 rose 12%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ALKS's Quality Score?

ALKS scores 11 today, which Breakaway calls Above Average (11 to 14). That is #19 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ALKS's 11.

Are insiders buying ALKS?

2 insiders sold $2.9M across 2 filings in the last 6 months. No open-⁠market buys on record. The newest is Nancy Lynn Snyderman, Director, who sold $2.2M on Aug 3. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.